CJC-1295 + Ipamorelin Blend
Growth Hormone Secretagogue Stack • Synergistic GH Release for Research
The CJC-1295 + Ipamorelin Blend is a popular research combination of two synthetic peptides that act as growth hormone (GH) secretagogues. CJC-1295 is a modified growth hormone-releasing hormone (GHRH) analog, while Ipamorelin is a selective ghrelin receptor agonist. Together, they work synergistically to stimulate the pituitary gland to release endogenous growth hormone, often studied for potential benefits in body composition, recovery, and anti-aging research.
Individual Peptide Profiles
CJC-1295 (often without DAC in blends)
Molecular Formula: C₁₅₂H₂₅₂N₄₄O₄₂ (No DAC)
Molecular Weight: ~3367.9 Da
Classification: Long-acting GHRH analog
Ipamorelin
Molecular Formula: C₃₈H₄₉N₉O₅
Molecular Weight: 711.86 Da
Classification: Selective growth hormone secretagogue (GHS)
Mechanisms of Action & Synergy
The blend targets complementary pathways for amplified, pulsatile GH release with minimal impact on other hormones:
- CJC-1295: Mimics GHRH, binding to receptors on the pituitary to increase GH synthesis and secretion. The version without DAC provides shorter, more physiologic pulses.
- Ipamorelin: Acts as a ghrelin mimetic, activating the ghrelin receptor to stimulate GH release while suppressing somatostatin (a GH inhibitor). Highly selective with low cortisol/prolactin elevation.
- Synergistic Effects: The dual stimulation of GHRH and ghrelin pathways results in significantly greater GH and IGF-1 elevation than either peptide alone, supporting research into muscle growth, fat metabolism, and recovery.
Potential Research Findings & Benefits (Preclinical/Human Studies)
| Area | Observed Effects in Models |
|---|---|
| Body Composition | Increased lean muscle mass, reduced body fat, and improved metabolic parameters. |
| Recovery & Repair | Enhanced tissue repair, faster recovery from exercise or injury, and improved sleep quality. |
| Growth Hormone Levels | Sustained, dose-dependent increases in GH and IGF-1 with preserved natural pulsatility. |
| Anti-Aging Research | Potential support for skin elasticity, energy, and overall vitality markers. |
| Performance | Improved exercise capacity, strength gains, and fat loss in research settings. |
Safety Profile & Limitations
Important: Preclinical and limited human data indicate generally good tolerability with low risk of cortisol or prolactin elevation compared to other secretagogues. Potential side effects may include injection-site reactions, flushing, or transient hunger. Long-term safety in humans is not fully established. For laboratory/research use only.
Key Research Gaps
- Large-scale, long-term human clinical trials are limited.
- Optimal dosing ratios, cycle lengths, and potential interactions require further study.
- Most data combine preclinical animal models with smaller human observational studies.
Reviews
There are no reviews yet.